(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 November 2009 (05.11.2009)

PCT

(10) International Publication Number
WO 2009/134404 A3

(51) International Patent Classification:
A61K 31/56 (2006.01) *A61K 8/49* (2006.01)
A61K 31/58 (2006.01) *A61Q 19/02* (2006.01)
A61P 17/00 (2006.01)

(21) International Application Number:
PCT/US2009/002658

(22) International Filing Date:
30 April 2009 (30.04.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/049,114 30 April 2008 (30.04.2008) US

(71) Applicant *(for all designated States except US)*: **NEW YORK UNIVERSITY OF SCHOOL OF MEDICINE** [US/US]; 650 First Avenue, New York, NY 10016 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ORLOW, Seth, J.** [US/US]; 9 East 96th Street, New York, NY 10128 (US). **KOMATSU, Li, Ni** [US/US]; 14108 Castle Blvd. #303, Silver Springs, MD 20904 (US).

(74) Agents: **MUNSON, Peter, R.** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, CA 94304 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: STEROIDAL COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF

Figure 1A







Figure 1B



I

(57) Abstract: A method for the identification of compounds) that control melanin synthesis (melanogenesis), and the preparation and use of such compounds, and compositions and formulations thereof to modify (e.g., inhibit) melanin production are disclosed. A representative compound of the invention is defined by formula I: Me I The compounds may be prepared as pharmaceutical and cosmetic compositions, and in one embodiment, may be prepared in combination with each other, and with other melanogenesis inhibiting formulations. The compounds, compositions and formulations of the invention may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.

WO 2009/134404 A3

ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
4 February 2010